Voloridge Investment Management
APLS

Voloridge Investment Management’s Apellis Pharmaceuticals APLS Stock Holding History

Voloridge Investment Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-461,186
Closed -$11.6M – 992
2025
Q4 		$11.6M Sell
461,186
-531,083
-54% -$12.5M 0.04% 539
2025
Q3 		$22.5M Buy
992,269
+523,559
+112% +$12.2M 0.08% 319
2025
Q2 		$8.11M Buy
468,710
+214,920
+85% +$3.98M 0.03% 611
2025
Q1 		$5.55M Sell
253,790
-92,095
-27% -$2.54M 0.02% 746
2024
Q4 		$11M Sell
345,885
-468,679
-58% -$14.1M 0.04% 544
2024
Q3 		$23.5M Buy
814,564
+125,456
+18% +$4.65M 0.09% 327
2024
Q2 		$26.4M Buy
+689,108
New +$31.2M 0.1% 288
2023
Q4 		– Sell
-54,263
Closed -$2.06M – 1149
2023
Q3 		$2.06M Sell
54,263
-89,139
-62% -$3.92M 0.01% 910
2023
Q2 		$13.1M Buy
143,402
+77,167
+117% +$6.66M 0.06% 394
2023
Q1 		$4.37M Buy
+66,235
New +$3.82M 0.02% 711
2022
Q4 		– Sell
-107,452
Closed -$7.34M – 1417
2022
Q3 		$7.34M Buy
+107,452
New +$6.36M 0.04% 535
2022
Q2 		– Sell
-73,426
Closed -$3.73M – 1414
2022
Q1 		$3.73M Sell
73,426
-2,736
-4% -$121K 0.02% 741
2021
Q4 		$3.6M Sell
76,162
-272,546
-78% -$10.7M 0.02% 837
2021
Q3 		$11.5M Buy
348,708
+193,909
+125% +$10.9M 0.07% 390
2021
Q2 		$9.78M Buy
+154,799
New +$7.99M 0.07% 417
2021
Q1 		– Sell
-7,901
Closed -$452K – 1371
2020
Q4 		$452K Buy
+7,901
New +$334K ﹤0.01% 1146
2020
Q1 		– Sell
-16,762
Closed -$513K – 1074
2019
Q4 		$513K Buy
+16,762
New +$464K 0.01% 810
2019
Q2 		– Sell
-11,798
Closed -$230K – 746
2019
Q1 		$230K Buy
+11,798
New +$186K 0.01% 864

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Voloridge Investment Management's APLS Position: Q1 2026 in Review

Voloridge Investment Management sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 461,186 shares — an estimated $11.6M sold.

Voloridge Investment Management first reported a position in APLS in Q1 2019 and held it in 18 quarters. The position peaked at $26.4M in Q2 2024. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Voloridge Investment Management reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Voloridge Investment Management sold 461,186 Apellis Pharmaceuticals shares in Q1 2026, an estimated $11.6M.
  • Voloridge Investment Management first reported a position in Apellis Pharmaceuticals in Q1 2019 and held it in 18 quarters.
  • Voloridge Investment Management's Apellis Pharmaceuticals position peaked at $26.4M in Q2 2024.
  • 323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Voloridge Investment Management's 13F filing for Q1 2026, filed 15 May 2026.